(3aR)-Selitrectinib

CAS No. 1350884-56-8

(3aR)-Selitrectinib( BAY 2731954 | (6RS)-LOXO-195 )

Catalog No. M28716 CAS No. 1350884-56-8

(6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 Get Quote
5MG 72 Get Quote
10MG 110 Get Quote
25MG 215 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (3aR)-Selitrectinib
  • Note
    Research use only, not for human use.
  • Brief Description
    (6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
  • Description
    (6RS)-LOXO-195 is a potent and selective Trk tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BAY 2731954 | (6RS)-LOXO-195
  • Pathway
    Tyrosine Kinase
  • Target
    Trk Receptor
  • Recptor
    Apoptosis|MARK3|MARK4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1350884-56-8
  • Formula Weight
    380.427
  • Molecular Formula
    C20H21FN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H][C@]12CCCN1c1ccn3ncc(C(=O)NC(C)CCc4ncc(F)cc24)c3n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Fangfang Li, et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression?in vitro?and?in vivo. Acta Pharm Sin B.2020 Feb;10(2):289-300.
molnova catalog
related products
  • Entrectinib

    Entrectinib (NMS-E628, RXDX-101, NMS-01191372) is a potent, ATP-competitive, orally available pan-TRK, ROS1 and ALK inhibitor with IC50 of 1/3/5/12/7 nM for TRKA/TRKB/TRKC/ALK/ROS1, respectively.

  • LM22A-4

    LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB;?IC50 : 47 nM in a fluorescence anisotropy assay).

  • Belizatinib

    A potent, dual ALK and TrkA, TrkB and TrkC inhibitor, exhibits high affinity for wild-type recombinant ALK kinase activity with IC50 of 0.7 nM.